Current status of etoposide in the management of small cell lung cancer

D. H. Johnson, J. D. Hainsworth, K. R. Hande, F. A. Greco

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Etoposide is a schedule-dependent drug with excellent activity against small cell lung cancer (SCLC). Single-agent etoposide achieves overall response rates ranging from 15% to 84%, depending on the schedule of drug administration and the characteristics of the treated population. The route of etoposide administration (intravenous versus oral) has little impact on response rate, provided appropriate dose adjustments are made for oral therapy. In combination with other active agents, etoposide has proven particularly effective in the management of SCLC. Etoposide can be substituted dor doxorubicin or vincristine in the cyclophosphamide, doxorubicin, and vincristine (CAV) regimen without loss of efficacy. The etoposide and cisplastin (EP) combination is thought to be synergistic and has proven to be an effective salvage regimen for CAV failures. A regimen that alternates CAV and EP has been found by some investigators to be modestly more effective against SCLC than CAV alone; however, EP alone may be as useful as an alternating regimen. Most studies to date have demonstrated that EP induction is at least as effective as any other standard induction regimen. However, EP has the potential advantage of being more easily integrated with thoracic radiation therapy (RT). This is particularly important in limited-disease patients: two recent pilot studies employing EP induction with hyperfractionated thoracic RT yielded 2-year survival rates of greater than 50%. These promising results are being evaluated further in an ongoing Phase III trial in the United States. The available data indicate that etoposide is one of the most active agents against SCLC and therefore should be included as a component of induction therapy in all patients. New schedules of etoposide administration warrant further study.

Original languageEnglish (US)
Pages (from-to)231-244
Number of pages14
JournalCancer
Volume67
Issue number1 SUPPL.
StatePublished - 1991

Fingerprint

Small Cell Lung Carcinoma
Etoposide
Vincristine
Doxorubicin
Cyclophosphamide
Drug Administration Schedule
Appointments and Schedules
Radiotherapy
Thorax
Population Characteristics
Intravenous Administration
Survival Rate
Research Personnel
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Johnson, D. H., Hainsworth, J. D., Hande, K. R., & Greco, F. A. (1991). Current status of etoposide in the management of small cell lung cancer. Cancer, 67(1 SUPPL.), 231-244.

Current status of etoposide in the management of small cell lung cancer. / Johnson, D. H.; Hainsworth, J. D.; Hande, K. R.; Greco, F. A.

In: Cancer, Vol. 67, No. 1 SUPPL., 1991, p. 231-244.

Research output: Contribution to journalArticle

Johnson, DH, Hainsworth, JD, Hande, KR & Greco, FA 1991, 'Current status of etoposide in the management of small cell lung cancer', Cancer, vol. 67, no. 1 SUPPL., pp. 231-244.
Johnson DH, Hainsworth JD, Hande KR, Greco FA. Current status of etoposide in the management of small cell lung cancer. Cancer. 1991;67(1 SUPPL.):231-244.
Johnson, D. H. ; Hainsworth, J. D. ; Hande, K. R. ; Greco, F. A. / Current status of etoposide in the management of small cell lung cancer. In: Cancer. 1991 ; Vol. 67, No. 1 SUPPL. pp. 231-244.
@article{02415141993447b3b43aedd8ea44f693,
title = "Current status of etoposide in the management of small cell lung cancer",
abstract = "Etoposide is a schedule-dependent drug with excellent activity against small cell lung cancer (SCLC). Single-agent etoposide achieves overall response rates ranging from 15{\%} to 84{\%}, depending on the schedule of drug administration and the characteristics of the treated population. The route of etoposide administration (intravenous versus oral) has little impact on response rate, provided appropriate dose adjustments are made for oral therapy. In combination with other active agents, etoposide has proven particularly effective in the management of SCLC. Etoposide can be substituted dor doxorubicin or vincristine in the cyclophosphamide, doxorubicin, and vincristine (CAV) regimen without loss of efficacy. The etoposide and cisplastin (EP) combination is thought to be synergistic and has proven to be an effective salvage regimen for CAV failures. A regimen that alternates CAV and EP has been found by some investigators to be modestly more effective against SCLC than CAV alone; however, EP alone may be as useful as an alternating regimen. Most studies to date have demonstrated that EP induction is at least as effective as any other standard induction regimen. However, EP has the potential advantage of being more easily integrated with thoracic radiation therapy (RT). This is particularly important in limited-disease patients: two recent pilot studies employing EP induction with hyperfractionated thoracic RT yielded 2-year survival rates of greater than 50{\%}. These promising results are being evaluated further in an ongoing Phase III trial in the United States. The available data indicate that etoposide is one of the most active agents against SCLC and therefore should be included as a component of induction therapy in all patients. New schedules of etoposide administration warrant further study.",
author = "Johnson, {D. H.} and Hainsworth, {J. D.} and Hande, {K. R.} and Greco, {F. A.}",
year = "1991",
language = "English (US)",
volume = "67",
pages = "231--244",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "1 SUPPL.",

}

TY - JOUR

T1 - Current status of etoposide in the management of small cell lung cancer

AU - Johnson, D. H.

AU - Hainsworth, J. D.

AU - Hande, K. R.

AU - Greco, F. A.

PY - 1991

Y1 - 1991

N2 - Etoposide is a schedule-dependent drug with excellent activity against small cell lung cancer (SCLC). Single-agent etoposide achieves overall response rates ranging from 15% to 84%, depending on the schedule of drug administration and the characteristics of the treated population. The route of etoposide administration (intravenous versus oral) has little impact on response rate, provided appropriate dose adjustments are made for oral therapy. In combination with other active agents, etoposide has proven particularly effective in the management of SCLC. Etoposide can be substituted dor doxorubicin or vincristine in the cyclophosphamide, doxorubicin, and vincristine (CAV) regimen without loss of efficacy. The etoposide and cisplastin (EP) combination is thought to be synergistic and has proven to be an effective salvage regimen for CAV failures. A regimen that alternates CAV and EP has been found by some investigators to be modestly more effective against SCLC than CAV alone; however, EP alone may be as useful as an alternating regimen. Most studies to date have demonstrated that EP induction is at least as effective as any other standard induction regimen. However, EP has the potential advantage of being more easily integrated with thoracic radiation therapy (RT). This is particularly important in limited-disease patients: two recent pilot studies employing EP induction with hyperfractionated thoracic RT yielded 2-year survival rates of greater than 50%. These promising results are being evaluated further in an ongoing Phase III trial in the United States. The available data indicate that etoposide is one of the most active agents against SCLC and therefore should be included as a component of induction therapy in all patients. New schedules of etoposide administration warrant further study.

AB - Etoposide is a schedule-dependent drug with excellent activity against small cell lung cancer (SCLC). Single-agent etoposide achieves overall response rates ranging from 15% to 84%, depending on the schedule of drug administration and the characteristics of the treated population. The route of etoposide administration (intravenous versus oral) has little impact on response rate, provided appropriate dose adjustments are made for oral therapy. In combination with other active agents, etoposide has proven particularly effective in the management of SCLC. Etoposide can be substituted dor doxorubicin or vincristine in the cyclophosphamide, doxorubicin, and vincristine (CAV) regimen without loss of efficacy. The etoposide and cisplastin (EP) combination is thought to be synergistic and has proven to be an effective salvage regimen for CAV failures. A regimen that alternates CAV and EP has been found by some investigators to be modestly more effective against SCLC than CAV alone; however, EP alone may be as useful as an alternating regimen. Most studies to date have demonstrated that EP induction is at least as effective as any other standard induction regimen. However, EP has the potential advantage of being more easily integrated with thoracic radiation therapy (RT). This is particularly important in limited-disease patients: two recent pilot studies employing EP induction with hyperfractionated thoracic RT yielded 2-year survival rates of greater than 50%. These promising results are being evaluated further in an ongoing Phase III trial in the United States. The available data indicate that etoposide is one of the most active agents against SCLC and therefore should be included as a component of induction therapy in all patients. New schedules of etoposide administration warrant further study.

UR - http://www.scopus.com/inward/record.url?scp=0026088127&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026088127&partnerID=8YFLogxK

M3 - Article

C2 - 1845846

AN - SCOPUS:0026088127

VL - 67

SP - 231

EP - 244

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 1 SUPPL.

ER -